TY - JOUR
T1 - Pharmacotherapy of postpartum depression
AU - Di Scalea, Teresa Lanza
AU - Wisner, Katherine L.
N1 - Funding Information:
KL Wisner is sponsored by NIMH: R01, Identification and Therapy for Postpartum Depression. NIMH R01, Anti-depressant Use during Pregnancy, NIMH R01, Antimanic Use during Pregnancy. By the State of Pennsylvania for Increasing Maternal Infant Mental Health Services; feasibility study for depression education for Nurse Family Partnerships (PA). Conference support was provided by the Fine Foundation and Staunton Farms Foundation. Support was also provided by the Heinz Foundation: Teens—Building Options and Opportunities for Mothers grant. Finally, support was provided by Nova-Gyne for the donation of transdermal placebo patches for an NIMH funded study of estradiol patch for postpartum depression treatment. T Lanza di Scalea states no conflict of interest.
PY - 2009
Y1 - 2009
N2 - Background: The prevalence and recurrence rates of postpartum depression (PPD) are 13 and 25%, respectively. Despite its detrimental impact on the health of the motherinfant dyad, there is a paucity of data in the literature regarding the efficacy of pharmacological treatment of PPD. Objectives: i) To review the literature on the use of antidepressants and hormonal supplements for the prevention and the treatment of PPD; ii) to give the authors' opinion on the current status of the pharmacological treatment of PPD; and iii) to discuss developments that are likely to be important in the future. Methods: An electronic search was performed by using PubMed, Medline, and PsychINFO. Inclusion criteria were: i) empirical articles in peer-reviewed English-language journals; ii) well-validated measures of depression; and iii) a uniform scoring system for depression among the sample. Results/conclusion: The electronic search yielded a total of 19 articles (12 on treatment and 7 on prevention of PPD) with the following study designs: eight randomized clinical trials (six using placebo control and two using active control groups), and 11 open-label studies. The selection of the specific antidepressant for a woman with PPD should derive from a personalized riskbenefit analysis.
AB - Background: The prevalence and recurrence rates of postpartum depression (PPD) are 13 and 25%, respectively. Despite its detrimental impact on the health of the motherinfant dyad, there is a paucity of data in the literature regarding the efficacy of pharmacological treatment of PPD. Objectives: i) To review the literature on the use of antidepressants and hormonal supplements for the prevention and the treatment of PPD; ii) to give the authors' opinion on the current status of the pharmacological treatment of PPD; and iii) to discuss developments that are likely to be important in the future. Methods: An electronic search was performed by using PubMed, Medline, and PsychINFO. Inclusion criteria were: i) empirical articles in peer-reviewed English-language journals; ii) well-validated measures of depression; and iii) a uniform scoring system for depression among the sample. Results/conclusion: The electronic search yielded a total of 19 articles (12 on treatment and 7 on prevention of PPD) with the following study designs: eight randomized clinical trials (six using placebo control and two using active control groups), and 11 open-label studies. The selection of the specific antidepressant for a woman with PPD should derive from a personalized riskbenefit analysis.
KW - Pharmacotherapy
KW - Postpartum depression
KW - Prevention
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=72949094611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72949094611&partnerID=8YFLogxK
U2 - 10.1517/14656560903277202
DO - 10.1517/14656560903277202
M3 - Review article
C2 - 19874247
AN - SCOPUS:72949094611
VL - 10
SP - 2593
EP - 2607
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 16
ER -